Prevention Protocols for Ambulatory Patients
Study & PI
|Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs Control (SARS-CoV-2 Non- Immune Plasma) among Adults Exposed to COVID-19 |
PI: Shmuel Shoham
|Enroll: 888-506-1199 or visit www.covidplasmatrial.org
This study will assess the efficacy and safety of Human Coronavirus Immune Plasma (HCIP) as prophylaxis in adults following recent, close contact exposure to COVID-19 who have not yet themselves developed symptoms of infection, and are at a high risk for severe illness. Eligible subjects, which can include health care personnel with high risk exposure, will be randomized in a 1:1 ratio to receive either HCIP or control plasma.
|Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection: The PROTECT Study|
PI: Mark Sulkowski
|Enroll: 410-314-1142 or email PROTECTemail@example.com
The PROTECT study is a prospective, randomized, blinded, controlled trial of two weekly subcutaneous injections of lambda interferon alpha-1a versus placebo. Study subjects are the non-hospitalized household contacts of individuals with confirmed COVID-19 infection who can be either negative (Prevention cohort) or positive (Treatment cohort) for SARS-CoV-2 at the time of study entry. All participants will be followed for an observation period of up to 10 weeks.
|COVID-19 Investigational Vaccine Study (CIR 339) Astra Zeneca|
PIs Anna Durbin MD and Kawsar Talaat, MD
|Center for Immunization Research
Enroll: 410-955-7283 or Email JHSPH.ProjectSAVE@jhu.edu